ATC Group: V03AB37 Idarucizumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V03AB37 in the ATC hierarchy

Level Code Title
1 V Various
2 V03 All other therapeutic products
3 V03A All other therapeutic products
4 V03AB Antidotes
5 V03AB37

Active ingredients in V03AB37

Active Ingredient

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity, approximately 300-fold more potent than the binding affinity of dabigatran for thrombin. The idarucizumab-dabigatran complex is characterised by a rapid on-rate and extremely slow off-rate resulting in a very stable complex. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect.

Related product monographs

Document Type Information Source  
 PRAXBIND Solution for injection MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.